Pharma BD Deal Intelligence
Enodia Therapeutics entered a research collaboration and license agreement with Pfizer to discover and develop Sec61 inhibitors against multiple collaboration targets. Enodia performs discovery activities to screen, optimize and develop candidates; following the collaboration term Pfizer is responsible for all clinical, manufacturing, regulatory and commercial activities. Enodia receives an undisclosed upfront payment and is eligible for research, development and sales milestone payments plus tiered royalties on net sales, with total potential deal value stated as exceeding $500 million. Enodia's platform enables selective Sec61 translocon modulation, inhibiting disease-driving proteins at the point of synthesis while preserving essential physiological translocon function.
← Browse all deals · How we score deals
More: 2026 deals · Pfizer Inc. deals